Clinical Practice Guidelines on Immunotherapy Recommendations for Inhalant Allergy

In February, the American Academy of Otolaryngology-Head and Neck Surgery Foundation published the “Clinical Practice Guideline: Immunotherapy for Inhalant Allergy” aimed to identify quality improvement opportunities and evidence-based recommendations for clinicians.

Allergen immunotherapy is administered to millions of patients and is generally delivered as subcutaneous immunotherapy or sublingual immunotherapy, according to the authors.

The recommendations outline specific goals, which include: (1) optimizing patient care, (2) promoting safe and effective therapy, (3) reducing unjustified variations in care, and (4) reducing the risk of harm.

The guideline’s target patient populations are individuals aged 5 years and older with allergic rhinitis, with or without allergic asthma, who are candidates for immunotherapy or treated with immunotherapy for their inhalant allergies.

“This guideline is intended to focus on evidence-based quality improvement opportunities judged most important by the guideline development group. It is not intended to be a comprehensive, general guide regarding the management of inhaled allergies with immunotherapy,” the authors wrote. “The statements in this guideline are not intended to limit or restrict care provided by clinicians based on their experience and assessment of individual patients.”

 

Reference:

Gurgel RK, Baroody FM, Damask CC, et al. Clinical practice guideline: immunotherapy for inhalant allergy. Otolaryngol Head Neck Surg. 2024;170 Suppl 1:S1-S42. doi: 10.1002/ohn.648